The CCL19 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population in which the CCL19 gene has been targeted for disruption, leading to loss of functional CCL19 chemokine expression. This polyclonal knockout model is derived from the HAP1 near-haploid human cell line and provides a heterogeneous knockout background that avoids clonal selection bias. It serves as a robust loss-of-function system for studying CCL19-dependent processes in a human cellular context.
The HAP1 cell line is a fibroblast-like, near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia model. HAP1 cells maintain a haploid chromosomal complement except for diploid chromosome 8 and a segment of chromosome 15, which simplifies genetic analysis and enhances the utility of gene disruption studies. This cell line supports high-throughput screening and consistent experimental reproducibility, making it a widely adopted platform for functional genomics and drug discovery applications in cancer biology.
CCL19 is a chemokine that directs lymphocyte and dendritic cell trafficking to lymphoid organs via binding to the CCR7 receptor, a process essential for adaptive immunity. Upon ligand engagement, CCR7 activates multiple downstream signaling cascades, including JAK2/STAT3, PI3K/AKT, and MAPK/ERK pathways, which regulate cytoskeletal reorganization, cell survival, and migration. CCL19 expression is induced by upstream inflammatory regulators such as TNF-alpha, IL-1beta, and CD40 ligand through NF-kB and STAT3, and its signaling modulates Rho GTPase activity to promote leukocyte transendothelial migration. Disruption of CCL19 therefore eliminates a critical chemoattractant signal, allowing researchers to dissect receptor-proximal and distal signaling events.
In the near-haploid HAP1 background, CCL19 knockout ablates both autocrine and paracrine chemokine signaling, enabling clean interpretation of CCR7-dependent and -independent phenotypes. This model is particularly valuable for investigating chemokine-driven cell migration and invasion mechanisms relevant to cancer metastasis, as HAP1 cells are amenable to live-cell imaging and quantitative migration assays. The simplified genome facilitates combinatorial CRISPR screens to identify synthetic interactions or compensatory pathways that sustain migration in the absence of CCL19.
These CCL19 knockout HAP1 polyclonal cells support a wide range of experimental applications, including Transwell migration and chemotaxis assays to quantify directional cell movement, Western blotting for phosphorylated STAT3, AKT, and ERK1/2 to monitor pathway activation, and RT-qPCR or flow cytometry to profile CCR7 surface expression. The model is suited for drug target validation in chronic inflammation, rheumatoid arthritis, and lymphoma, as well as genetic interaction screens to uncover modulators of chemokine signaling. For technical assistance or ordering information, please contact Ascent Research.
